超低剂量全身[18F]-FDG PET/CT在结直肠癌中的初步应用
该回顾性研究纳入62例结直肠癌患者,评估超低剂量(0.37 MBq/kg)[18F]-FDG全身PET/CT的图像质量及病灶检出能力。通过将15分钟采集数据拆分为1至13分钟模拟快速扫描,发现所有64个原发灶在各时间组均可识别,但淋巴结和肝转移检出率随采集时间缩短而下降。结论认为超低剂量全身PET/CT在结直肠癌中可保持满意的图像质量和病灶检出能力。
要点
- 超低剂量0.37 MBq/kg全身PET/CT在结直肠癌中可行
- 所有原发灶在短至1分钟采集图像中均可识别
- 淋巴结和肝转移检出率随采集时间缩短而降低
核心结论
- 超低剂量[18F]-FDG全身PET/CT在结直肠癌中可维持满意的图像质量和病灶检出能力。
研究设计与样本
- 回顾性研究纳入62例接受超低剂量(0.37 MBq/kg)[18F]-FDG全身PET/CT的结直肠癌患者。
- 将15分钟采集数据拆分为13、8、5、4、3、2、1分钟模拟快速扫描图像,以G15为对照评估病灶检出。
主要发现
- 主观评分G15最高(4.5±0.5),从G13(4.3±0.4)降至G8(3.7±0.5)。
- 肝脏SNR从G8(17.2±2.8)增至G13(20.6±3.4)和G15(21.9±3.4),G8与G13无显著差异(p=0.15),与G15有显著差异(p=0.001)。
- 所有64个结直肠癌原发灶在所有图像组(包括G1)均可识别。
- 以G15为对照,淋巴结检出率G13和G8为100%(48/48),G5和G4为93.8%(45/48),G3为85.4%(41/48),G2为81.3%(39/48),G1为77.1%(37/48)。
- 肝转移灶在G13和G8无遗漏,G5、G4、G3、G2、G1分别遗漏3、4、6、7、9个;肺、腹膜、卵巢转移在所有组均无遗漏。
关键数值与推荐
- 超低剂量定义为0.37 MBq/kg [18F]-FDG。
- 主观图像质量采用5分Likert量表评估。
- 客观参数包括肝和血池的SUVmax、SUVmean、SNR及病灶SUVmax和TBR。
临床怎么用
- 超低剂量全身PET/CT可用于结直肠癌原发灶检出,但缩短采集时间需权衡淋巴结和肝转移检出率。
- 8分钟采集可保持淋巴结100%检出且无肝转移遗漏,可作为快速扫描的参考。
局限性
- 回顾性研究,样本量有限(62例)。
- 未报告辐射剂量、患者BMI等可能影响图像质量的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study was to evaluate the effects of an ultra-low dose of [18F]-FDG on the image quality of total-body PET/CT and its lesion detectability in colorectal cancer (CRC). METHODS: Sixty-two CRC patients who underwent total-body PET/CT (uEXPLORER, United Imaging Healthcare, Shanghai, China) with an ultra-low dose (0.37 MBq/kg) of [18F]-FDG were enrolled in this retrospective study. The PET images were reconstructed with the entire 15-min dataset first and then split into 13-, 8-, 5-, 4-, 3-, 2-, and 1-min duration groups to simulate fast scanning images. For simplicity, the images reconstructed with the data from 15 to 1 min were referred to as G15, G13, and so on until G1. Subjective image quality was assessed with 5-point Likert scales. The objective image quality parameters included the SUVmax, SUVmean, and signal-to-noise ratio (SNR) of the liver and blood pool and the SUVmax and tumor-to-background ratio (TBR) of the lesions. G15 served as the control to evaluate lesion detectability. RESULTS: A total of 62 patients (43 men, 19 women; age 41-88, mean ± SD 64.0 ± 10.9 years) with 64 CRC primary tumor lesions and 10 low-grade intraepithelial neoplasia (LGIN) lesions were enrolled in this study. The subjective scores were highest for G15 (4.5 ± 0.5) and then decreased from G13 (4.3 ± 0.4) to G8 (3.7 ± 0.5). The liver SNR increased with the extension of acquisition time from G8 (17.2 ± 2.8) to G13 (20.6 ± 3.4) and G15 (21.9 ± 3.4). The liver SNR of G8 was not significantly different from that of G13 (p = 0.15) and was significantly different from that of G15 (p = 0.001). All 64 CRC lesions could be identified in all image groups, even on G1. One of ten LGINs was missed on G1, G2, and G3, and one LGIN was missed on G1, G2, G3, and G4. G15 served as the control, and 100% (48/48) lymph nodes could be found on G13 and G8 compared to 93.8% (45/48) lymph nodes on G5 and G4, 85.4% (41/48) lymph nodes on G3, 81.3% (39/48) lymph nodes on G2, and 77.1% (37/48) lymph nodes on G1. For liver metastases, there were no missed liver lesions on G13 and G8 and 3, 4, 6, 7, and 9 missed liver lesions on G5, G4, G3, G2, and G1, respectively. For other areas of metastasis, including the lung, peritoneum, and ovaries, there were no missed lesions in any group. CONCLUSIONS: Total-body PET/CT with an ultra-low dose of [18F]-FDG can maintain satisfactory image quality and lesion detectability in CRC.
引用
- Tan H, Cai D, Sui X, et al. Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience. Eur J Nucl Med Mol Imaging. 2021. PMID: 34462790. doi:10.1007/s00259-021-05537-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。